Study Reveals Long COVID Risk Elevated in Autoimmune Rheumatic Patients
A recent analysis indicates that individuals with autoimmune rheumatic diseases face a significantly higher risk of developing Long COVID.
Long COVID prevalence is 2.8% in AIRD patients compared to 1.5% in controls.
Factors like obesity and specific treatments increase Long COVID risk.
Clinicians are urged to monitor high-risk patients for Long COVID symptoms.
A recent study has found that individuals suffering from autoimmune rheumatic diseases (AIRD) are at a greater risk of developing Long COVID compared to those without these conditions. The research, conducted in the United States, analyzed data from a large cohort of patients who had their first documented SARS-CoV-2 infection between September 2021 and December 2023, with follow-ups extending to December 2024.
The study utilized data from the National Clinical Cohort Collaborative (N3C) and included a matched cohort of 187,106 patients. Long COVID was identified based on specific diagnostic codes or clinic visits occurring 28 to 365 days post-infection. The findings revealed that 2.8% of patients with AIRD developed Long COVID, whereas only 1.5% of the control group experienced the same condition. This indicates a significant disparity in risk associated with autoimmune rheumatic diseases.
In-depth analyses highlighted that AIRD patients had an adjusted hazard ratio of 1.56 for developing Long COVID, indicating a 56% increased risk compared to non-AIRD individuals. Additional factors contributing to this heightened risk included severe acute COVID-19 symptoms, existing pulmonary diseases, obesity, and exposure to treatments such as rituximab or glucocorticoids. Notably, patients with Sjögren’s syndrome were also found to be at an increased risk for Long COVID.
The implications of these findings are profound, as they underscore the necessity for healthcare providers to identify and monitor risk factors in patients with AIRD. The heightened risk of Long COVID in this population calls for increased vigilance and proactive management to mitigate long-term health consequences. Clinicians are encouraged to remain alert for symptoms of Long COVID, particularly in patients exhibiting higher-risk characteristics.
Looking ahead, further research is essential to validate these associations and enhance understanding of Long COVID in patients with autoimmune rheumatic diseases. Continued investigation will be crucial in developing targeted strategies for prevention and management in this vulnerable population.
